{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:22:51Z","timestamp":1789593771409,"version":"build-2803163510"},"reference-count":97,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>mmune checkpoint inhibitors have reshaped the therapeutic landscape of advanced gastric and gastroesophageal junction cancer, yet durable benefit remains restricted to biologically selected patient subgroups. Optimizing immunotherapy, therefore, requires a disease-specific, clinically practical, and critically interpreted biomarker framework rather than reliance on any single predictive marker. This review synthesizes established and emerging biomarkers for immune checkpoint inhibitor selection in advanced, metastatic, and perioperative gastric cancer, with emphasis on programmed death-ligand 1 combined positive score, deficient mismatch repair\/microsatellite instability-high status, tumor mutational burden, Epstein\u2013Barr virus-associated tumors, HER2-defined combination strategies, tumor microenvironment features, circulating tumor DNA dynamics, and artificial intelligence-assisted models. In addition to summarizing biological rationale, this review critically evaluates trial-based limitations that influence biomarker interpretation, including assay variability, spatial and temporal heterogeneity, dynamic PD-L1 expression, inconsistent CPS thresholds, overlap between TMB-high and MSI-H biology, and the limited prospective validation of exploratory markers. Recent perioperative and neoadjuvant ICI studies are discussed to highlight how early biomarker testing may guide treatment intensification, de-escalation, or trial selection in resectable disease. Emerging evidence supporting TMEscore, longitudinal ctDNA response, and multimodal AI-based prediction is also examined, with an emphasis on the current barriers to routine clinical implementation. Finally, this review proposes a tiered, resource-aware interpretation of biomarkers that distinguishes clinically actionable markers from investigational tools and addresses challenges related to standardization, cost, access, and equity. Overall, biomarker-guided integration of molecular, immune, dynamic, and translational markers is essential to improve patient selection and advance precision immunotherapy in gastric cancer.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1775386","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:20:10Z","timestamp":1782919210000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Optimizing immunotherapy in advanced gastric cancer: established and emerging biomarkers for precision patient selection"],"prefix":"10.3389","volume":"17","author":[{"given":"Xianjun","family":"Rao","sequence":"first","affiliation":[{"name":"Wangjing Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guodong","family":"Huang","sequence":"additional","affiliation":[{"name":"Wangjing Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxuan","family":"Li","sequence":"additional","affiliation":[{"name":"College of Traditional Chinese Medicine, Hubei University of Chinese Medicine","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyu","family":"Wu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Heilongjiang University of Chinese Medicine","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pediatric Surgery, The Sixth Affiliated Hospital of Harbin Medical University","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianfeng","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixing","family":"Qian","sequence":"additional","affiliation":[{"name":"College of Traditional Chinese Medicine, Hubei University of Chinese Medicine","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liji","family":"Chen","sequence":"additional","affiliation":[{"name":"College of Traditional Chinese Medicine, Hubei University of Chinese Medicine","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[{"name":"Wangjing Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[{"name":"Wangjing Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: A Cancer J For Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21657","article-title":"Current treatment and recent progress in gastric cancer","volume":"71","author":"Joshi","year":"2021","journal-title":"CA: A Cancer J For Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","year":"2014","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3850","article-title":"Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes","volume":"21","author":"Cristescu","year":"2015","journal-title":"Nat Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-2275","article-title":"Advances in HER2-targeted therapy: novel agents and opportunities beyond breast and gastric cancer","volume":"25","author":"Meric-Bernstam","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ejca.2022.08.023","article-title":"Recent progress and current challenges of immunotherapy in advanced\/metastatic esophagogastric adenocarcinoma","volume":"176","author":"Moehler","year":"2022","journal-title":"Eur J Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"885","DOI":"10.2217\/imt-2022-0012","article-title":"Immune checkpoint inhibitors in luminal gastrointestinal Malignancies: Going beyond MSI-H\/dMMR, TMB and PD-L1","volume":"14","author":"Lefler","year":"2022","journal-title":"Immunotherapy"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10102108","article-title":"The emerging role of liquid biopsy in gastric cancer","volume":"10","author":"Lengyel","year":"2021","journal-title":"J Clin Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.1038\/s41467-019-11788-4","article-title":"Macrophage spatial heterogeneity in gastric cancer defined by multiplex immunohistochemistry","volume":"10","author":"Huang","year":"2019","journal-title":"Nat Commun"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.902017","article-title":"Discovering immune-mediated mechanisms of gastric carcinogenesis through single-cell RNA sequencing","volume":"13","author":"Hoft","year":"2022","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23126664","article-title":"Immunotherapy as a therapeutic strategy for gastrointestinal cancer\u2014current treatment options and future perspectives","volume":"23","author":"Koustas","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/4697670","article-title":"Gastroenterological cancer and immunotherapy","volume":"2018","author":"Wang","year":"2018","journal-title":"Can J Gastroenterol Hepatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13073-022-01024-y","article-title":"A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape","volume":"14","author":"Long","year":"2022","journal-title":"Genome Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.948647","article-title":"Recent progress and future perspectives of immunotherapy in advanced gastric cancer","volume":"13","author":"Jin","year":"2022","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btac641","article-title":"Predicting colorectal cancer tumor mutational burden from histopathological images and clinical information using multi-modal deep learning","volume":"38","author":"Huang","year":"2022","journal-title":"Bioinformatics"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/1440-1681.13028","article-title":"The roles of PD\u20101\/PD\u2010L1 and its signalling pathway in gastrointestinal tract cancers","volume":"46","author":"Cui","year":"2019","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13045-017-0511-2","article-title":"PD-1\/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy","volume":"10","author":"Long","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110504","article-title":"Research progress of PD-1\/PD-L1 immunotherapy in gastrointestinal tumors","volume":"129","author":"Sun","year":"2020","journal-title":"Biomedicine Pharmacotherapy"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i28.6362","article-title":"Immunotherapy in human colorectal cancer: challenges and prospective","volume":"22","author":"Sun","year":"2016","journal-title":"World J Gastroenterol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.slasd.2021.12.003","article-title":"DeepTI: A deep learning-based framework decoding tumor-immune interactions for precision immunotherapy in oncology","volume":"27","author":"Ma","year":"2022","journal-title":"SLAS Discov"},{"key":"B21","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.18632\/aging.204134","article-title":"Exploring immune-related signatures for predicting immunotherapeutic responsiveness, prognosis, and diagnosis of patients with colon cancer","volume":"14","author":"Cao","year":"2022","journal-title":"Aging (Albany NY)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2023.06.004","article-title":"Deep Learning\u2013based stratification of gastric cancer patients from hematoxylin and eosin\u2013stained whole slide images by predicting molecular features for immunotherapy response","volume":"193","author":"Wei","year":"2023","journal-title":"Am J Pathol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13249","article-title":"Biomarkers of immune checkpoint inhibitor response and toxicity: challenges and opportunities","volume":"318","author":"Goodman","year":"2023","journal-title":"Immunol Rev"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21114012","article-title":"Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies","volume":"21","author":"Machlowska","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.2010.00781.x","article-title":"Pathogenesis of Helicobacter pylori infection","volume":"19","author":"Kusters","year":"2006","journal-title":"Clin Microbiol Rev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.32074\/1591-951x-166","article-title":"Precancerous lesions of the stomach, gastric cancer and hereditary gastric cancer syndromes","volume":"112","author":"Gullo","year":"2020","journal-title":"Pathologica"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2021.101730","article-title":"The impact of recent next generation sequencing and the need for a new classification in gastric cancer","volume":"50","author":"Businello","year":"2021","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.121459","article-title":"Current progress and challenges of immunotherapy in gastric cancer: A focus on CAR-T cells therapeutic approach","volume":"318","author":"Entezam","year":"2023","journal-title":"Life Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-019-02724-4","article-title":"Thirty years of Epstein-Barr virus-associated gastric carcinoma","volume":"476","author":"Fukayama","year":"2020","journal-title":"Virchows Arch"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2018.01.004","article-title":"Hereditary gastrointestinal carcinomas and their precursors: An algorithm for genetic testing","volume":"35","author":"Spoto","year":"2018","journal-title":"Semin Diagn Pathol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2021.101820","article-title":"Hereditary diffuse gastric cancer (HDGC). An overview","volume":"46","author":"Taja-Chayeb","year":"2022","journal-title":"Clinics Res Hepatol Gastroenterol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2021.101728","article-title":"Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS)\u2013A Helicobacter-opposite point","volume":"50","author":"Tacheci","year":"2021","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2022.101800","article-title":"Familial and hereditary gastric cancer, an overview","volume":"58","author":"Carneiro","year":"2022","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15037","article-title":"Gastric cancer prevention strategies: A global perspective","volume":"35","author":"Eusebi","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1122121","article-title":"Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort","volume":"14","author":"Jiang","year":"2023","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2022.06.036","article-title":"Use of fluorescence imaging and indocyanine green for sentinel node mapping during gastric cancer surgery: Results of an intercontinental Delphi survey","volume":"172","author":"Sherwinter","year":"2022","journal-title":"Surgery"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35831","article-title":"Perioperative chemotherapy for gastric cancer patients with microsatellite instability or deficient mismatch repair: A systematic review and meta\u2010analysis","volume":"131","author":"Liu","year":"2025","journal-title":"Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.00686","article-title":"Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability\u2013high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study","volume":"41","author":"Andr\u00e9","year":"2023","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.11.016","article-title":"Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO","volume":"36","author":"Raimondi","year":"2025","journal-title":"Ann Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00975","article-title":"Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II\/III DANTE\/IKF-s633 trial","volume":"42","author":"Lorenzen","year":"2024","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02758-x","article-title":"Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial","volume":"30","author":"Verschoor","year":"2024","journal-title":"Nat Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2024","journal-title":"Lancet Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2503701","article-title":"Perioperative durvalumab in gastric and gastroesophageal junction cancer","volume":"393","author":"Janjigian","year":"2025","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(24)00156-0","article-title":"Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Kang","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.01124","article-title":"Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer","volume":"37","author":"Pietrantonio","year":"2019","journal-title":"J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2020.100036","article-title":"Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials","volume":"6","author":"Pietrantonio","year":"2021","journal-title":"ESMO Open"},{"key":"B48","doi-asserted-by":"publisher","first-page":"177","DOI":"10.5230\/jgc.2025.25.e4","article-title":"PD-L1 as a biomarker in gastric cancer immunotherapy","volume":"25","author":"Cho","year":"2024","journal-title":"J Gastric Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade\u2013based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"B50","doi-asserted-by":"publisher","first-page":"32925","DOI":"10.18632\/oncotarget.9076","article-title":"Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers","volume":"7","author":"Derks","year":"2016","journal-title":"Oncotarget"},{"key":"B51","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03133-7","article-title":"First-line tislelizumab plus chemotherapy for advanced gastric cancer with programmed death-ligand 1 expression \u2265 1%: a retrospective analysis of RATIONALE-305","volume":"42","author":"Moehler","year":"2025","journal-title":"Adv Ther"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"Jama"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"},{"key":"B56","doi-asserted-by":"publisher","first-page":"14027","DOI":"10.1038\/s41598-024-63486-x","article-title":"Plasma circulating tumor DNA unveils the efficacy of PD-1 inhibitors and chemotherapy in advanced gastric cancer","volume":"14","author":"Jiang","year":"2024","journal-title":"Sci Rep"},{"key":"B57","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s43856-025-00867-x","article-title":"Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma","volume":"5","author":"Tougeron","year":"2025","journal-title":"Commun Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","article-title":"The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors","volume":"7","author":"Davis","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B59","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1208\/s12248-020-00514-4","article-title":"Identification and utilization of biomarkers to predict response to immune checkpoint inhibitors","volume":"22","author":"Gjoerup","year":"2020","journal-title":"AAPS J"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)31257-1","article-title":"Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial","volume":"392","author":"Shitara","year":"2018","journal-title":"Lancet"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/s0304-3959(02)00153-7","article-title":"Involvement of local cholecystokinin in the tolerance induced by morphine microinjections into the periaqueductal gray of rats","volume":"102","author":"Tortorici","year":"2003","journal-title":"Pain"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"Bmj"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1200\/po.24.00230","article-title":"PD-L1 immunohistochemistry in gastric cancer: comparison of combined positive score and tumor area positivity across 28-8, 22C3, and SP263 assays","volume":"8","author":"Klempner","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"5095","DOI":"10.1038\/s41467-022-32816-w","article-title":"Noninvasive imaging of the tumor immune microenvironment correlates with response to immunotherapy in gastric cancer","volume":"13","author":"Huang","year":"2022","journal-title":"Nat Commun"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107753","article-title":"Tumor microenvironment as a therapeutic target in cancer","volume":"221","author":"Xiao","year":"2021","journal-title":"Pharmacol Ther"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/2549295","article-title":"Neutrophil\u2010to\u2010lymphocyte ratio (NLR) predicts PD\u20101 inhibitor survival in patients with metastatic gastric cancer","volume":"2021","author":"Gou","year":"2021","journal-title":"J Immunol Res"},{"key":"B68","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41698-024-00533-w","article-title":"Tertiary lymphoid structures predict survival and response to neoadjuvant therapy in locally advanced rectal cancer","volume":"8","author":"Wang","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3390\/biom13121803","article-title":"Neutrophil-to-lymphocyte ratio (NLR) in NSCLC, gastrointestinal, and other solid tumors: immunotherapy and beyond","volume":"13","author":"Mosca","year":"2023","journal-title":"Biomolecules"},{"key":"B70","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13045-022-01294-4","article-title":"Exploring immunotherapy in colorectal cancer","volume":"15","author":"Weng","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002467","article-title":"Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer","volume":"9","author":"Zeng","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/j.medj.2024.07.006","article-title":"Tumor microenvironment RNA test to predict immunotherapy outcomes in advanced gastric cancer: The TIMES001 trial","volume":"5","author":"Shi","year":"2024","journal-title":"Med"},{"key":"B73","doi-asserted-by":"publisher","first-page":"4851","DOI":"10.1038\/s41467-022-32570-z","article-title":"Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment","volume":"13","author":"Chen","year":"2022","journal-title":"Nat Commun"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1097\/pai.0000000000000941","article-title":"Intrapatient tumor heterogeneity in IHC interpretation using PD-L1 IHC 22C3 pharmDx","volume":"29","author":"Kalpakoff","year":"2021","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz116","article-title":"ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1\/PD-L1 expression and tumour mutational burden: a systematic review-based approach","volume":"30","author":"Luchini","year":"2019","journal-title":"Ann Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.07.020","article-title":"Deficient mismatch repair\/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment","volume":"175","author":"Taieb","year":"2022","journal-title":"Eur J Cancer"},{"key":"B78","doi-asserted-by":"publisher","first-page":"e180013","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/jco.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair\u2013deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.02462","article-title":"Mismatch repair and microsatellite instability testing for immune checkpoint inhibitor therapy: ASCO endorsement of College of American Pathologists guideline","volume":"41","author":"Vikas","year":"2023","journal-title":"J Clin Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.803","article-title":"Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma","volume":"32","author":"Shitara","year":"2021","journal-title":"Ann Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-0121","article-title":"Association of tumor mutational burden with efficacy of pembrolizumab\u00b1chemotherapy as first-line therapy for gastric cancer in the phase III KEYNOTE-062 study","volume":"28","author":"Lee","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04508-4","article-title":"Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer","volume":"603","author":"Shitara","year":"2022","journal-title":"Nature"},{"key":"B84","doi-asserted-by":"publisher","first-page":"476","DOI":"10.5230\/jgc.2023.23.e29","article-title":"The optimal tumor mutational burden cutoff value as a novel marker for predicting the efficacy of programmed cell death-1 checkpoint inhibitors in advanced gastric cancer","volume":"23","author":"Jang","year":"2023","journal-title":"J Gastric Cancer"},{"key":"B85","doi-asserted-by":"publisher","first-page":"219","DOI":"10.5230\/jgc.2026.26.e14","article-title":"Predictive value of insertion\/deletion rate in patients with gastric cancer treated with nivolumab plus chemotherapy","volume":"26","author":"Kim","year":"2026","journal-title":"J Gastric Cancer"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz197","article-title":"Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib\/II clinical trial NCT02915432","volume":"30","author":"Wang","year":"2019","journal-title":"Ann Oncol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-13-0661","article-title":"Targeting the tumor microenvironment: from understanding pathways to effective clinical trials","volume":"73","author":"Fang","year":"2013","journal-title":"Cancer Res"},{"key":"B88","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.cell.2019.10.003","article-title":"Landscape and dynamics of single immune cells in hepatocellular carcinoma","volume":"179","author":"Zhang","year":"2019","journal-title":"Cell"},{"key":"B89","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00527","article-title":"Contribution to tumor angiogenesis from innate immune cells within the tumor microenvironment: implications for immunotherapy","volume":"9","author":"Albini","year":"2018","journal-title":"Front Immunol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0856-x","article-title":"Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors","volume":"26","author":"Schalper","year":"2020","journal-title":"Nat Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003536","article-title":"Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer","volume":"9","author":"Alessi","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B94","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/cco.0000000000000223","article-title":"Liquid biopsy enters the clinic\u2014implementation issues and future challenges","volume":"18","author":"Ignatiadis","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-025-01621-x","article-title":"Circulating tumor DNA predicts clinical benefits of immune checkpoint blockade in HER2-negative patients with advanced gastric cancer: M. He et\u00a0al","volume":"28","author":"He","year":"2025","journal-title":"Gastric Cancer"},{"key":"B96","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1186\/s12967-024-05262-z","article-title":"Deep learning based digital pathology for predicting treatment response to first-line PD-1 blockade in advanced gastric cancer","volume":"22","author":"Liu","year":"2024","journal-title":"J Transl Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217930","article-title":"Multimodal radiopathomics signature for prediction of response to immunotherapy-based combination therapy in gastric cancer using interpretable machine learning","volume":"631","author":"Huang","year":"2025","journal-title":"Cancer Lett"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1775386\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:20:11Z","timestamp":1782919211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1775386\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":97,"alternative-id":["10.3389\/fimmu.2026.1775386"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1775386","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"1775386"}}